5,900 Shares of Veeva Systems Inc. $VEEV Bought by Westwind Capital

Westwind Capital acquired a new stake in shares of Veeva Systems Inc. (NYSE:VEEV) during the third quarter, Holdings Channel reports. The firm acquired 5,900 shares of the technology company’s stock, valued at approximately $1,684,000.

A number of other hedge funds have also modified their holdings of the stock. Fundsmith LLP acquired a new stake in Veeva Systems in the 2nd quarter valued at $144,955,000. Arrowstreet Capital Limited Partnership grew its position in Veeva Systems by 203.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 913,281 shares of the technology company’s stock valued at $160,427,000 after acquiring an additional 611,868 shares during the period. Swedbank AB raised its stake in Veeva Systems by 43.5% during the first quarter. Swedbank AB now owns 1,645,128 shares of the technology company’s stock worth $288,983,000 after acquiring an additional 498,971 shares in the last quarter. Pictet Asset Management Holding SA raised its stake in Veeva Systems by 43.6% during the first quarter. Pictet Asset Management Holding SA now owns 1,593,795 shares of the technology company’s stock worth $279,970,000 after acquiring an additional 483,720 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in shares of Veeva Systems by 757.5% during the first quarter. Pacer Advisors Inc. now owns 485,046 shares of the technology company’s stock valued at $85,203,000 after acquiring an additional 428,478 shares during the period. 88.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

VEEV has been the topic of several analyst reports. UBS Group upped their target price on shares of Veeva Systems from $190.00 to $290.00 and gave the stock a “neutral” rating in a report on Thursday, August 27th. Needham & Company LLC boosted their price objective on Veeva Systems from $270.00 to $310.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. Royal Bank Of Canada increased their target price on Veeva Systems from $275.00 to $325.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Wells Fargo & Company reissued an “overweight” rating and set a $330.00 price objective on shares of Veeva Systems in a report on Tuesday, September 8th. Finally, Canaccord Genuity Group raised their price objective on shares of Veeva Systems from $220.00 to $260.00 and gave the company a “hold” rating in a research report on Thursday, August 27th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Veeva Systems presently has a consensus rating of “Moderate Buy” and an average target price of $284.88.

Key Stories Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva Basics adoption is expanding. More than 175 emerging biotechs are using the preconfigured platform across clinical, regulatory, quality, medical, and commercial operations. The announcement supports Veeva’s ability to win customers early and expand them as they advance toward commercialization. Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development
• Positive Sentiment: Clinical-data automation is showing meaningful scale. Veeva says its Development Quality Solution has cleaned data for more than 1 million clinical-trial subjects across over 1,000 studies, highlighting customer usage and the potential for automation to improve retention and cross-selling. Veeva’s DQS Scales Data Automation Across 1,000+ Clinical Studies
• Positive Sentiment: Management is highlighting continued platform momentum. CEO Peter Gassner said nearly 200 customers are using Veeva Basics, while the upcoming R&D and Quality Summit will showcase AI tools and customer use cases involving Eli Lilly, Pfizer, Sanofi, UCB, and others. The event may reinforce Veeva’s positioning as an important software provider for modern drug development. Veeva Summit to Showcase AI Innovations
• Positive Sentiment: Technical momentum remains strong. Market commentary says VEEV is nearing several buy points as institutional money returns to software companies with sticky enterprise customers. Veeva’s entrenched position in pharma data and workflows is viewed as a potential AI-era advantage. Software Leader Veeva Systems Positioned To Hit Buy Points After Nearly Doubling

Veeva Systems Stock Up 0.8%

VEEV stock traded up $2.28 during midday trading on Thursday, reaching $284.78. The stock had a trading volume of 921,680 shares, compared to its average volume of 2,342,119. The firm has a market cap of $46.11 billion, a price-to-earnings ratio of 46.84, a PEG ratio of 1.21 and a beta of 0.93. Veeva Systems Inc. has a twelve month low of $148.05 and a twelve month high of $303.39. The business has a fifty day simple moving average of $259.17 and a two-hundred day simple moving average of $202.93.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.23 by $0.12. Veeva Systems had a net margin of 29.34% and a return on equity of 14.25%. The company had revenue of $927.96 million for the quarter, compared to analyst estimates of $905.38 million. During the same quarter last year, the firm earned $1.99 EPS. The company’s revenue for the quarter was up 17.6% on a year-over-year basis. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, equities analysts predict that Veeva Systems Inc. will post 6.7 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Priscilla Hung sold 750 shares of the firm’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $261.04, for a total value of $195,780.00. Following the transaction, the director directly owned 3,242 shares in the company, valued at $846,291.68. This trade represents a 18.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Rizzo sold 4,841 shares of Veeva Systems stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $276.51, for a total value of $1,338,584.91. Following the sale, the executive vice president directly owned 7,665 shares of the company’s stock, valued at approximately $2,119,449.15. This trade represents a 38.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 51,591 shares of company stock valued at $13,355,945 in the last 90 days. 10.60% of the stock is owned by company insiders.

Veeva Systems Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company’s product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.